Robert Bitterman - Phio Pharmaceuticals Independence Chairman of the Board
| PHIO Stock | USD 1.47 0.10 6.37% |
Chairman
Mr. Robert J. Bitterman is an Independence Chairman of the Board of RXI Pharmaceuticals Corporationrationration. Prior to joining the Company, Mr. Bitterman has served as a member and the Chairman of our Board of Directors since 2012. Prior to joining the Company, Mr. Bitterman founded Cutanea Life Sciences, Inc. in September 2005 as its President, Chief Executive Officer and Board Director. Cutanea Life Sciences, Inc. focuses on the development and commercialization of proprietary technologies to treat diseased and aging skin and was successfully acquired by Maruho Company, LTD. in February 2012, where Mr. Bitterman has continued his role as President and Chief Executive Officer. Mr. Bitterman also served as President and General Manager of Dermik Laboratories, the global dermatology strategic business unit of Aventis S.A. from 1994 to 2004. Mr. Bitterman held various positions of increasing responsibility in financial and commercial capacities within Aventis S.A. From September 2004 until April 2005, Mr. Bitterman also held the position of President and Chief Executive Officer of Isolagen, Inc., a publicly traded bioscience technology company which developed and commercialized autologous human fibroblasts targeting soft tissue enhancement since 2013.
| Age | 74 |
| Tenure | 12 years |
| Professional Marks | MBA |
| Phone | 508 767 3861 |
| Web | https://phiopharma.com |
Robert Bitterman Latest Insider Activity
Tracking and analyzing the buying and selling activities of Robert Bitterman against Phio Pharmaceuticals stock is an integral part of due diligence when investing in Phio Pharmaceuticals. Robert Bitterman insider activity provides valuable insight into whether Phio Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Phio Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Phio Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Robert Bitterman over six months ago Acquisition by Robert Bitterman of 1000 shares of Phio Pharmaceuticals at 0.74 subject to Rule 16b-3 | ||
Robert Bitterman over six months ago Acquisition by Robert Bitterman of 1000 shares of Phio Pharmaceuticals at 0.75 subject to Rule 16b-3 | ||
Robert Bitterman over six months ago Acquisition by Robert Bitterman of 40000 shares of Phio Pharmaceuticals subject to Rule 16b-3 | ||
Robert Bitterman over six months ago Acquisition by Robert Bitterman of 2000 shares of Phio Pharmaceuticals at 0. subject to Rule 16b-3 |
Phio Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.6107) % which means that it has lost $0.6107 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2686) %, meaning that it created substantial loss on money invested by shareholders. Phio Pharmaceuticals' management efficiency ratios could be used to measure how well Phio Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 6 records | CHAIRMAN Age | ||
| BA MD | 180 Life Sciences | 76 | |
| Sir Feldmann | 180 Life Sciences | 80 | |
| Jack MD | Ocean Biomedical | 73 | |
| Stephen Glover | ZyVersa Therapeutics | 65 | |
| Jonathan MD | Ocean Biomedical | 56 | |
| Pankaj Mohan | Sonnet Biotherapeutics Holdings | 60 | |
Management Performance
| Return On Equity | -1.27 | ||||
| Return On Asset | -0.61 |
Phio Pharmaceuticals Corp Leadership Team
Elected by the shareholders, the Phio Pharmaceuticals' board of directors comprises two types of representatives: Phio Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Phio. The board's role is to monitor Phio Pharmaceuticals' management team and ensure that shareholders' interests are well served. Phio Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Phio Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Bitterman, Independence Chairman of the Board | ||
| Esq CPA, CFO Officer | ||
| Dr MedSc, Interim Director | ||
| Linda Mahoney, Senior Development | ||
| Jim Cardia, VP Operations | ||
| Caitlin Kontulis, VP Secretary |
Phio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Phio Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.27 | ||||
| Return On Asset | -0.61 | ||||
| Current Valuation | (477.66 K) | ||||
| Shares Outstanding | 860.72 K | ||||
| Shares Owned By Insiders | 5.89 % | ||||
| Shares Owned By Institutions | 2.07 % | ||||
| Number Of Shares Shorted | 99.59 K | ||||
| Price To Earning | (0.80) X | ||||
| Price To Book | 1.61 X | ||||
| Price To Sales | 48.01 X |
Pair Trading with Phio Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Phio Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Phio Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Phio Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Phio Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Phio Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Phio Pharmaceuticals Corp to buy it.
The correlation of Phio Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Phio Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Phio Pharmaceuticals Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Phio Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phio Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Phio Pharmaceuticals. If investors know Phio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Phio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Phio Pharmaceuticals Corp is measured differently than its book value, which is the value of Phio that is recorded on the company's balance sheet. Investors also form their own opinion of Phio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Phio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Phio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Phio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Phio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Phio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Phio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.